Cortexyme, Inc. is a biopharmaceutical company that develops treatments for Alzheimer's and other degenerative diseases. Their main drug candidate, atuzaginstat (COR388), is a small molecule gingipain inhibitor that is currently being tested in Phase II/III clinical trials for mild to moderate Alzheimer's disease and other conditions. The company was established in 2012 and is based in South San Francisco, California.